Methods	Randomised, double-blind, placebo-controlled, 3-way cross-over, not enriched. No imputation method mentioned Titration over 4 weeks to pain control, limit of tolerability, or maximum amitriptyline 150 mg daily, gabapentin 3600 mg daily, then stable dose for remainder of 8-week period; 1-week washout then cross-over Analysis for completers only
Participants	SCI at any level and degree of completeness. N = 38, only 22 patients completed all three cross-overs. Mean age 43 years, 9% women. Pain duration before treatment > 6 months, PI at randomisation > 5/10, initial pain intensity 5.6/10
Interventions	Amitriptyline 150 mg daily (max) Gabapentin 3600 mg daily (max) Placebo (diphenhydramine) 75 mg daily Oxycodone + paracetamol 5/325 mg (max 8 tablets daily) allowed for rescue medication
Outcomes	No dichotomous data for efficacy or harm Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Yes	Prepared, packaged and labelled by remote, commercial compounding pharmacy
Blinding? All outcomes	Yes	“identical capsules”
Incomplete outcome data addressed? Efficacy	No	Completers only
Size Efficacy	No	38 randomised
Study duration Efficacy	Yes	8-week period
Outcomes reported	No	No dichotomous data